Technical Study: Zoetis Inc., Teva Pharma Industries Ltd, Covidien plc, and Valeant Pharma Intl. Inc.

LONDON, August 21, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Tuesday August 20, 2013, the S&P 500 ended at 1,652.35, up 0.38% and the NASDAQ composite closed at 3,613.59, up 0.68%. Shares in healthcare sector companies mostly ended on a higher note, tracking gains in the broader market. The movers in the sector included Zoetis Inc. (NYSE: ZTS), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Covidien PLC (NYSE: COV), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). AAAResearchReports.com free coverage on ZTS, TEVA, COV, and VRX is available upon registration at:

http://www.aaaresearchreports.com/register/

Zoetis Inc.'s stock rose sharply on Tuesday as the broader market edged higher. The company's shares traded between $29.71 and $30.41 before closing the day 1.21% higher at $30.23. A total of 3.80 million shares were traded, which is significantly below the daily average volume of 9.14 million. The company's stock has gained 0.70% in the previous three trading sessions, outperforming the S&P 500 which has declined by 0.54% during the same period. Download free technical research on ZTS by signing up at:

http://www.AAAResearchReports.com/ZTS082113.pdf

Shares in Teva Pharmaceutical Industries Ltd fell sharply on Tuesday, extending losses from previous trading sessions. The company's shares ended the day at $39.13, down 1.16%, after fluctuating between $39.10 and $39.69. A total of 3.78 million shares were traded, which is marginally above the daily average volume of 3.72 million. The company's shares have dropped 2.42% in the last one month and 2.64% in the last three months, underperforming the S&P 500 during the same period. Furthermore, Teva Pharmaceutical Industries Ltd's stock is trading marginally above its 200-day moving average of $39.11. Register now and get access to free analysis on TEVA at:

http://www.AAAResearchReports.com/TEVA082113.pdf

On Tuesday, Covidien PLC's stock traded between $60.76 and $61.20 before finishing the day 0.10% higher at $60.96. A total of 1.70 million shares were traded, which is below the daily average volume of 2.53 million. The company's shares have gained 2.25% in the last three months, outperforming the S&P 500 which has fallen by 0.84% during the same period. Additionally, Covidien PLC's shares are trading above their 50-day and 200-day moving averages. Sign up and read our complimentary report on COV at:

http://www.AAAResearchReports.com/COV082113.pdf

Shares in Valeant Pharmaceuticals International Inc. ended higher on Tuesday, tracking gains in the broader market. The company's shares vacillated between $100.78 and $102.45 before finishing the day 0.47% higher at $101.53. A total of 0.80 million shares were traded, which is below the daily average volume of 1.89 million. The stock has fallen 1.36% in the previous three trading sessions. Despite recent losses, the company's shares have gained 11.82% in the last one month and 34.69% in the last three months, outperforming the S&P 500 which has declined by 2.35%and 0.84% during the same periods. The free report on VRX can be downloaded by signing up now at:

http://www.AAAResearchReports.com/VRX082113.pdf

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.AAAresearchreports.com

SOURCE AAA Research Reports